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oligodendroglioma and the rest had GBM. There was a clear 
inverse correlation between Ki-67 percentage staining and 
overall survival. In patients with Ki-67 ≤ 30% (n=18), 5 year 
survival was approximately 50% compared to those with Ki-67 
>30% (n=60) with survival of 10% (logrank P-value 0.02, HR 
0.39, 95% CI 0.17 – 0.88). 
 
Conclusion: There appears to be a correlation between 
percentage staining of Ki-67 and overall survival in patients 
with HGG. Percentage staining of Ki-67 > 30% appears to 
predict for poorer survival in HGG. 
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Purpose or Objective:Background and purpose:In this 
retrospective evaluation, we correlated radiation dose 
parameters with occurrence of optical radiation-induced 
toxicities. 
 
Material and Methods: Patients and methods:213 
meningiomapatientsreceived radiation between 2000 and 
2013. Radiation dose and clinical datawere extracted from 
planning systems and patients’ files. The range of follow-up 
period was 2-159 months (median:75 months). 
 
Results: Results:Median age of patients was 60 years (range: 
23-86). There were163 female and 50 male patients. In 140 
cases, at least one of the neuro-optic structures (optic nerves 
and chiasm) was inside the irradiatedtarget volumes. We 
found 15 dry eye (7%) and 24 cataract (11.2%) cases. Median 
dose to affected lachrymal glands was 1.47Gy and median 
dose to affected lenses was1.05Gy. Age and blood cholesterol 
level in patients with cataract were significantly higher. 
Patients with dry eye were significantly older. Only 2 patients 
with visual problems attributable to radiation treatment 
(RION) were seen. They did not have any risk factors. 
Maximum and median delivered doses to neuro-optic 
structures were not higher than 57.30Gy and 54.60Gy 
respectively. 
 
Conclusion: Conclusion:Low percentages of cases with 
radiation induced high grade optic toxicities show that 
modern treatment techniques and doses are safe. In very few 
patients with optic side effects, doses to organs at risk were 
higher than the defined constraint doses. This observation 
leads to the problem of additional risk factors coming into 
play. The role of risk factors and safety of higher radiation 
doses in high grade meningiomas should be investigated in 
more comprehensive studies. 
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Purpose or Objective: Evaluating the radiation doses 
delivered to different parts of the visual pathway for better 
understanding of light vision in radiotherapy patients. 
 
Material and Methods: 20 patients with brain tumors and 
head and neck malignancies who received radiotherapy and 
experienced any kind of light or color vision during radiation 
treatment. All the components of visual pathway including 
lenses, eyeballs, retinas, optic nerves, chiasm, optic tracts, 
optic radiations and visual occipital cortexes were contoured. 
 
Results: 11 patients were male (55%) and 9 were female 
(45%). Age median was 56 years. The range of dose/fraction 
and total prescribed dose were 1.8-3 Gy and 36-70.4 Gy 
respectively. Twelve patients reported white, 11, blue, 2, 
yellow and 2, gray color visions. Seven patients experienced 
more than one color, while 2 patients did not attribute any 
special color to their light seeing experiences. Four patients 
had a kind of smell experience and 1 patient had a taste 
experience. 
 
Conclusion: Cherenkov radiation in eye ballsmay be the 
origin of light seeing experiences in patients receiving 
radiation treatment for head and neck malignancies, since 
treatmentsareperformed with ionizing radiations with 
energycapable to produce this effect. Also this effectmay be 
due to phosphenes produced by radiation treatment in 
different parts of the visual pathway (from retina to visual 
cortex). In order to investigate the mechanism of this 
phenomenon in patients and to define a radiation dose 
threshold – if the origin of this phenomenon is phosphenes 
produced in visual pathway – larger studies are needed. 
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Purpose or Objective: Ependymomas are central nervous 
system (CNS) tumors that due to their rare prevalence have 
considerable controversy regarding their prognostic factors 
and clinical management. As such, many of the reported 
series involve accumulation of patient data that spans many 
decades, making current management decisions difficult. In 
this study, we report the outcomes and possible prognostic 
factors of patients with histologically confirmed 
infratentorial ependymomas treated in the modern era. 
 
Material and Methods: A retrospective chart review of our 
patient registry was conducted to identify 15 patients 
diagnosed with infratentorial ependymoma between 2007—
2013. Mean age at diagnosis was 29 years (range 1.0—79.0 
years). There were 8 males and 7 females, with headache 
being the most common presenting symptom among the 
entire cohort. Eleven were newly diagnosed with 
ependymoma and the remaining 4 were recurrent patients 
who had failed primary therapy. Of the newly diagnosed 
patients, all received surgery and post-operative radiation 
therapy (RT) with a mean dose of 54.3 Gy (range 45.0—59.4 
Gy). Two also received chemotherapy. Patients in the 
recurrent group experienced only local recurrences after 
initial treatment and underwent salvage RT with a mean dose 
of 45.6 Gy (range 15.0—59.4 Gy). 
 
Results: With a mean follow-up time of 15 months (range 
1.4—61.7 months) for the cohort, a significant difference in 
overall survival (OS) was found between primary and 
recurrent patients (p=0.0082). Overall, 9 patients (60%) had 
no acute complications with the remainder Grade I or II 
following initial treatment. All were free of late 
complications throughout follow-up. Moreover, there were no 
statistically significant differences in OS or local control 
when tumor size or RT dose were analyzed.  
 
Conclusion: Our findings indicate that recurrence is a 
prognostic factor for decreased OS in patients with 
infratentorial ependymomas. Involved field radiation therapy 
following surgical resection of these tumors offers high local 
